BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
BC Innovations | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BC Innovations | Jun 8, 2017
Translation in Brief

Damage potential

Although cancer drugs have proven effective in treating autoimmune diseases, their intolerable long-term toxicity has discouraged new players from exploring their potential. A group at University of Cincinnati has discovered a new combination that kills...
BioCentury | Jun 8, 2015
Product Development

Overcoming origins

The start of two large-scale trials enrolling patients whose tumors share a common molecular signature regardless of the tissue of origin reflects tremendous progress in both the understanding of cancer biology and the availability of...
BC Week In Review | Jun 1, 2015
Clinical News

AZD1775: Phase II data

Data from 22 evaluable patients with p53-mutated refractory or resistant ovarian cancer in an open-label, Dutch Phase II trial showed that first-line treatment with twice-daily 225 mg oral AZD1775 for 2.5 days plus carboplatin led...
BC Week In Review | Jun 1, 2015
Clinical News

AZD1775: Phase II data

An open-label, international, 2-part Phase II trial in 121 patients with platinum-sensitive, p53-mutated ovarian cancer showed that twice-daily 225 mg oral AZD1775 for the first 2.5 days of each 21-day cycle plus paclitaxel and carboplatin...
BioCentury | Jun 9, 2014
Product Development

Sum of PARPs

Data for olaparib plus cediranib presented at the American Society of Clinical Oncology meeting show the ovarian cancer therapies may be able to achieve unprecedented gains in progression-free survival when used in combination. Whether the...
BC Week In Review | Feb 3, 2014
Clinical News

Mekinist trametinib: Phase II started

NIH's National Cancer Institute (NCI) began the single-blind Phase II M-PACT trial to evaluate whether treatment based on specific gene mutations improves the rate and duration of response in patients with advanced, refractory solid tumors....
BC Extra | Jan 31, 2014
Clinical News

NCI starts trial of targeted cancer treatments

NIH's National Cancer Institute launched the single-blind Phase II M-PACT trial to evaluate whether treatment based on specific gene mutations improves the rate and duration of response in patients with advanced, refractory solid tumors. The...
Items per page:
1 - 10 of 15